The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...

Investing.com -- Shares of Hims & Hers Health, Inc. (NYSE: HIMS) climbed 30% following the announcement of a long-term ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity. Consumers will now be able to access ...

Eli Lilly faced a reality check as HSBC downgraded its stock twice, citing inflated optimism about its weight-loss drugs. Wall Street is underestimating the risk to Lilly from its main weight-loss ...

Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven ...

The US Food and Drug Administration seized fake Ozempic injections. This happened on April 9, 2025. Novo Nordisk warned about ...

Danish drugmaker Novo Nordisk has partnered with Hims & Hers Health's to sell its popular weight loss drug through a bundled ...

The companies, which have at times had an adversarial relationship, also said they would develop a roadmap to continue their ...

Hundreds of thousands of people flocked to these compounding firms when they didn't have enough money to afford the costly ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

A Howard County man is suing Novo Nordisk, alleging Ozempic caused him to go blind after using the drug to treat diabetes. He seeks damages in court.

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...